GLP-1 Receptor Agonists: What They Are and How They Work

• Explains GLP-1 agonists by active ingredient rather than brand
• Separates single GLP-1 and dual-pathway medicines
• Covers oral and injectable medicine formats
• Clarifies the current position of emerging triple agonists

You may have heard the term "GLP-1" everywhere lately, but it does not describe just one medicine.

GLP-1 stands for glucagon-like peptide-1, a hormone involved in appetite, digestion and blood sugar control. GLP-1 receptor agonists are medicines that mimic some of the effects of this hormone by activating the GLP-1 receptor. Some are used to treat type 2 diabetes, while others are authorised for weight management. Newer medicines can also act on more than one hormone pathway, which makes the terminology even more confusing.

For adults in the UK considering prescription treatment, the important thing is to look beyond the label "GLP-1". Different medicines have different active ingredients, authorised uses, doses, routes of administration and safety information.

This guide explains what GLP-1 receptor agonists are, how they work, how they differ from dual agonists such as tirzepatide, what is currently authorised in the UK, and why a medicine's exact active ingredient and licensed use matter.

Key things to know

• GLP-1 stands for glucagon-like peptide-1.
• GLP-1 receptor agonists mimic some of the effects of a natural hormone released after eating.
• They can increase feelings of fullness and are also used in the treatment of type 2 diabetes.
• Not every GLP-1 medicine is authorised for weight management.
• Tirzepatide is a dual GIP and GLP-1 receptor agonist, rather than a GLP-1 receptor agonist alone.
• GLP-1 medicines can be available as injections or tablets, depending on the exact product.
• Prescription weight management medicines are used alongside dietary and physical activity measures where appropriate.
• Triple agonists that target GLP-1, GIP and glucagon are still an emerging area and should not be presented as established UK treatments without checking current MHRA authorisation.
• The suitability of any prescription medicine depends on the individual and the exact product.

What Are GLP-1 Agonist Medications?

The full term is GLP-1 receptor agonists. These are medicines that activate the GLP-1 receptor and mimic some of the effects of the naturally occurring GLP-1 hormone. (MHRA guidance)

The MHRA explains that GLP-1 medicines can help people feel fuller by mimicking a hormone released after eating. Some are also used to help manage blood glucose in people with type 2 diabetes.

However, the term GLP-1 does not tell you exactly what a medicine is authorised to treat. For example, semaglutide is used in different medicinal products, and those products do not all have the same authorised uses. The exact product therefore matters as much as the active ingredient.

What Does GLP-1 Actually Do?

GLP-1 is a hormone naturally produced by the body. It is released after eating and plays a role in appetite and blood glucose regulation.

GLP-1 receptor agonist medicines mimic some of this activity. One effect is that they can increase feelings of fullness, which can affect how much a person wants to eat.

It is important not to turn this into the idea that GLP-1 medicines simply "burn fat". Where a medicine is authorised for weight management, it is used as part of a wider treatment approach that can include changes to diet and physical activity.

What Are the Main GLP-1 Agonist Names?

This is where things can get confusing because people often use brand names, active ingredients and drug classes interchangeably.

For understanding the pharmacology, the active ingredient is usually the clearest place to start.

The product still needs to be checked because the same active ingredient can appear in different medicinal products with different authorised uses. For example, the MHRA distinguishes between Wegovy, Ozempic and Rybelsus, even though they contain semaglutide.

Is Tirzepatide a GLP-1 Agonist?

It acts on the GLP-1 receptor, but calling tirzepatide simply a GLP-1 agonist misses an important part of how it works.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In other words, it acts on the GLP-1 receptor as well as the receptor for glucose-dependent insulinotropic polypeptide, known as GIP.

This distinction matters when comparing medicines. "GLP-1 medicine" is often used as a broad term in everyday conversation, but it does not mean that every medicine in the group works in exactly the same way.

Are All GLP-1 Agonist Drugs Used for Weight Loss?

No.

This is one of the most important points to understand if you are researching these medicines online.

The MHRA states that not all GLP-1 medicines are authorised for weight loss. For example, Wegovy is authorised for weight management, while Ozempic and Rybelsus are licensed for type 2 diabetes rather than weight management. The exact indication depends on the medicinal product.

So, if you are looking for a weight loss treatment, do not assume that any medicine containing a GLP-1 receptor agonist is automatically suitable or authorised for that purpose.

Which Medicines Does NICE List for Weight Management?

Current NICE guidance includes tirzepatide, semaglutide, liraglutide and orlistat among medicines that may be used for weight management when the relevant criteria are met.

These medicines do not all belong to the same drug class.

Orlistat, for example, works in the digestive system by reducing the absorption of some dietary fat. It is not a GLP-1 receptor agonist.

NICE also gives medicine-specific information about where and how different treatments are prescribed. For example, the route, frequency and prescribing setting can differ between tirzepatide, semaglutide, liraglutide and orlistat.

This is why "weight loss medicine" and "GLP-1 medicine" should not be treated as interchangeable terms.

How Are GLP-1 Agonists Used for Weight Management?

When a GLP-1 medicine is authorised and clinically appropriate for weight management, it is used as part of a wider plan.

NICE recommends that medicines for weight management are used alongside dietary, physical activity and behavioural support. The exact approach depends on the medicine and the person's circumstances.

The MHRA also makes clear that GLP-1 medicines are not intended as a quick way to lose weight or for people who want to lose weight purely for aesthetic or cosmetic reasons.

Treatment can also require ongoing review. What happens after stopping a medicine can vary, and weight regain is possible for some people. This is one reason weight management is generally treated as a longer term issue rather than a short course.

Are GLP-1 Agonists Available as Pills?

Yes. It is no longer accurate to describe all GLP-1 medicines as injections.

In June 2026, the MHRA approved oral semaglutide tablets for weight management in certain adults. In August 2026, the MHRA also authorised orforglipron, another oral GLP-1 receptor agonist, for weight management and type 2 diabetes.

This does not mean that every GLP-1 medicine is available as a tablet. The route of administration depends on the exact product.

It also does not mean that oral GLP-1 medicines are available over the counter. These are prescription medicines and still require appropriate clinical assessment.

Is an Oral GLP-1 Agonist the Same as an Injection?

Not necessarily.

Two medicines can affect the same broad biological pathway while having different active ingredients, formulations, doses and instructions.

Even when the active ingredient is the same, an oral and injectable formulation should not be treated as automatically interchangeable. The product information and prescribing instructions should be followed.

If you are considering changing from an injection to a tablet, speak to your prescriber rather than making the change yourself.

What Is a Dual GLP-1 and GIP Agonist?

A dual agonist acts on two receptor pathways.

Tirzepatide is currently the key example used in UK weight management. It acts on both GIP and GLP-1 receptors, which makes it different from medicines that activate the GLP-1 receptor alone.

This does not mean that one class can simply be described as "better" than another. They are different medicines with different pharmacological profiles, prescribing considerations and evidence.

What Is a GLP-1, GIP and Glucagon Triple Agonist?

A triple agonist is designed to act on three receptor pathways: GLP-1, GIP and glucagon.

This is an area of ongoing medicine development and research. It is important to separate medicines being studied in clinical trials from medicines that are authorised and available for routine treatment.

For UK healthcare content, a triple agonist should not be presented as an established weight management option unless its current MHRA authorisation has been confirmed.

Is There a UK Approved Triple Agonist for Weight Loss?

There is currently no established UK weight management treatment that should be described as a GLP-1, GIP and glucagon triple agonist based simply on research or development announcements.

Current NICE weight management guidance includes established options such as tirzepatide, semaglutide, liraglutide and orlistat.

The MHRA, ASA and GPhC have also warned businesses against promoting unlicensed medicines and pipeline products for weight management.

This is an important distinction. A medicine can show interesting results in research without being authorised for routine use in the UK.

Why Does UK Authorisation Matter?

A medicine's regulatory status tells you whether it has been assessed and authorised for a particular use.

The MHRA assesses medicines for safety, quality and effectiveness before granting a marketing authorisation. However, authorisation applies to the specific medicinal product and its approved uses.

So the useful question is not simply:

"Is this a GLP-1?"

It is:

"What is the exact medicine, what is it authorised to treat, and is it appropriate for this person?"

That small difference can prevent a lot of confusion when reading information online.

How Do GLP-1 Agonist Medications Differ From Each Other?

There is more to comparing these medicines than looking at the words "GLP-1".

They can differ in their active ingredient, receptor targets, formulation, route of administration, authorised use, eligibility criteria and safety information.

For example, the MHRA has updated safety information for semaglutide following reports of very rare NAION, a condition affecting the optic nerve. The regulator has also strengthened warnings about acute pancreatitis for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.

This does not mean that these effects are common. It shows why medicine-specific safety information matters.

Does a Dual Agonist Work the Same Way as a GLP-1 Agonist?

No.

A GLP-1 receptor agonist targets the GLP-1 receptor. A dual GIP and GLP-1 receptor agonist, such as tirzepatide, targets two pathways.

The distinction is useful because medicines that are often grouped together online can have different mechanisms and prescribing information.

When comparing treatments, it is better to look at the exact active ingredient and product information rather than assuming that all modern weight management medicines work in the same way.

Would a Triple Agonist Be the Same as Current GLP-1 Drugs?

No.

A triple agonist is designed to act on three pathways, while a GLP-1 receptor agonist acts on the GLP-1 receptor and a dual agonist acts on two pathways.

It is also important to remember that being developed or studied does not mean that a medicine is available for routine treatment.

Research findings can be useful, but regulatory approval is a separate step.

Why Should You Search GLP-1 Agonists by Active Ingredient?

Searching by active ingredient can make it easier to understand what you are actually reading about.

For example:

• Semaglutide is a GLP-1 receptor agonist.
• Liraglutide is a GLP-1 receptor agonist.
• Tirzepatide is a dual GIP and GLP-1 receptor agonist.
• Orlistat is a weight management medicine but is not a GLP-1 receptor agonist.

Brand names still matter because the same active ingredient can appear in different products with different authorised uses.

The MHRA's current guidance is a useful example. It lists semaglutide under Wegovy, Ozempic and Rybelsus, but the licensed uses differ between these products.

Does One Active Ingredient Always Have the Same Authorised Use?

No.

This is particularly important with semaglutide.

The MHRA lists Wegovy as authorised for weight management, while Ozempic and Rybelsus are licensed for type 2 diabetes.

So knowing the active ingredient is helpful, but it is not the whole picture. You should also check the exact medicinal product and its authorised indication.

Are New Oral GLP-1 Agonists Prescription Medicines?

Yes.

The fact that a medicine comes as a tablet does not make it an over the counter product.

The MHRA has authorised oral GLP-1 receptor agonists for specific medical uses, including oral semaglutide for weight management and orforglipron for weight management and type 2 diabetes. These remain prescription medicines.

Are Oral GLP-1 Agonists Easier to Use?

That depends on the person and the exact medicine.

Some people may prefer a tablet to an injection, while others may find an injectable treatment easier to fit into their routine.

There are also product-specific instructions to consider. For example, dose increases, timing and other administration requirements can vary between medicines.

The most convenient option is not necessarily the most suitable one. Your prescriber can discuss the available treatments and help you understand the practical differences.

Can You Switch From an Injectable GLP-1 Agonist to Pills?

Do not make this change on your own.

The MHRA advises people to speak with their prescriber before making changes such as switching between GLP-1 medicines.

Whether a switch is appropriate depends on the exact medicines involved, their doses, your medical history and the reason you are taking treatment.

Can You Combine Two GLP-1 Agonist Drugs?

Do not combine GLP-1 medicines unless this has been specifically prescribed and reviewed by an appropriate healthcare professional.

For example, NICE's prescribing guidance states that people already taking a GLP-1 receptor agonist for diabetes should not take tirzepatide at the same time.

Taking two medicines that affect related pathways is not something to experiment with yourself. If you are considering a change in treatment, discuss it with your prescriber.

Who May Be Considered for a GLP-1 Receptor Agonist for Weight Loss?

Being interested in weight loss does not automatically mean that a GLP-1 medicine is appropriate.

Eligibility depends on the exact medicine and its authorised criteria. A clinical assessment may consider BMI, weight related health conditions, medical history, current medicines and other factors.

Different medicines can have different eligibility requirements, so there is no single BMI or checklist that applies to every GLP-1 medicine.

Does GLP-1 Treatment Replace Diet and Physical Activity?

No.

Medicine is only one part of weight management.

NICE recommends that weight management medicines are used alongside dietary, physical activity and behavioural support.

This does not mean you have to follow a perfect diet or exercise routine. It means that medication is generally considered alongside practical changes that support your health.

How Long Can GLP-1 Agonist Treatment Continue?

There is no single treatment length that applies to every GLP-1 medicine.

How long treatment continues can depend on the exact medicine, its authorised use, how well it is working, side effects, medical circumstances and the treatment criteria that apply.

Some treatments also have specific review points. Your prescriber can explain what applies to the medicine you are taking.

What Side Effects Are Monitored During GLP-1 Treatment?

Like all medicines, GLP-1 treatments can cause side effects. Gastrointestinal effects such as nausea, vomiting and diarrhoea are among the commonly reported problems with this group, although the exact side effect profile varies by medicine.

During treatment, a healthcare professional may review:

• how you are responding to treatment;
• whether you are experiencing side effects;
• your current medicines;
• relevant changes in your health;
• your weight management progress; and
• whether continuing treatment remains appropriate.

Acute pancreatitis is an uncommon but potentially serious side effect associated with GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. The MHRA advises people to be alert for severe, persistent stomach pain, which may spread to the back and may occur with nausea or vomiting. Urgent medical assessment is needed if these symptoms occur.

The exact safety advice depends on the medicine you are prescribed.

What if a GLP-1 Agonist Does Not Work as Expected?

It can be frustrating when your experience does not match what you have read online.

Try not to compare your response with another person's result. Different people can respond differently to the same medicine.

If you are concerned that your treatment is not helping, speak to your prescriber. They can review your dose, treatment plan, side effects, other medicines and wider health circumstances before deciding whether anything should change.

Do not increase your dose or switch medicines without medical advice.

Are GLP-1 Agonist Medications Available Over the Counter?

No. GLP-1 medicines used for these medical purposes are prescription medicines in the UK.

This applies to oral and injectable treatments. Taking a tablet does not remove the need for appropriate prescribing and clinical assessment.

Be cautious of websites offering GLP-1 medicines without a proper prescription or clinical process. The MHRA has warned about illegally supplied weight loss medicines and advises people to use legitimate supply routes.

Can GLP-1 Agonists Be Accessed Online in the UK?

Some legitimate healthcare services can provide a clinical assessment online.

However, an online consultation should not mean automatic approval for treatment. A prescriber still needs to decide whether the medicine is suitable based on the information provided.

If a website appears to guarantee approval, asks you to bypass normal prescribing requirements or offers prescription medicines without an appropriate assessment, take extra care.

How Can You Check Whether a GLP-1 Medicine Is Legitimate?

If you are researching a medicine online, a few simple checks can help.

1. Check the active ingredient.
2. Check the exact product and its authorised use.
3. Make sure a qualified prescriber is involved.
4. Check that the medicine is supplied through a legitimate pharmacy.
5. Look for medicine specific information and instructions.
6. Be cautious of products that are offered without a prescription when a prescription is required.

The MHRA has specifically warned people about illegal online weight loss medicines and products that have not been properly authorised.

Why Are Unauthorised GLP-1 Products a Concern?

A product using the words "GLP-1" is not automatically a legitimate GLP-1 medicine.

Products obtained outside the regulated supply chain may not contain what the seller claims, and their quality, strength, storage or handling may not have been properly controlled.

This is one reason the MHRA, ASA and GPhC have warned businesses about promoting unlicensed medicines and pipeline products for weight management.

If you are unsure about a medicine, check its regulatory status and speak to a qualified healthcare professional or pharmacist.

How Should New Triple Agonist Claims Be Assessed?

This is where it helps to slow down.

A medicine can be discussed in research, tested in clinical trials and reported in the news long before it becomes an authorised treatment.

When you see a claim about a new triple agonist, check three separate things:

1. Is it being studied in clinical research?
2. Has it received UK regulatory authorisation?
3. Is it actually appropriate and available for the person being treated?

Those are three different questions.

For healthcare content, an investigational medicine should remain clearly described as investigational unless its current UK regulatory status has been verified.

What Is the Most Useful Way to Understand GLP-1 Agonists UK?

If all the terminology feels confusing, start with the pathway rather than the brand name.

GLP-1 receptor agonist → acts on the GLP-1 receptor

Dual GIP and GLP-1 receptor agonist → acts on GIP and GLP-1 receptors

Triple GLP-1, GIP and glucagon agonist → designed to act on three pathways and requires separate confirmation of regulatory status

This simple distinction can make it easier to understand why medicines that are often grouped together online are not necessarily the same treatment.

Medical Disclaimer

GLP-1 receptor agonists and related medicines are prescription treatments with medicine specific authorised uses, eligibility requirements and safety considerations.

This article provides general information about GLP-1 receptor agonists, oral and injectable formulations, dual agonists and emerging triple agonists. It does not provide personalised prescribing or dosing advice and does not replace an assessment by an appropriately qualified healthcare professional.

If you are taking a GLP-1 medicine and have concerns about side effects, pregnancy, other medicines or changing treatment, speak to your prescriber or pharmacist. Do not change your dose or stop treatment without medical advice.